---
canonical_name: Dihydromyricetin
alternate_names: DHM, Ampelopsin, Ampeloptin, DMY
canonical_topic: Dihydromyricetin for Skin Rejuvenation
short_topic_lc: dihydromyricetin_skin
creation_date: 2026-0720-0424
creator_ai_fullname: Opus 4.8
---

# Dihydromyricetin for Skin Rejuvenation
<section id="top" markdown="1"></section>

Evidence Review created on 07/20/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8

**Also known as:** DHM, Ampelopsin, Ampeloptin, DMY


## Motivation

<!-- This motivation section was written last, after the rest of the document was completed, so that it reflects the full scope of the topic. -->

Dihydromyricetin (DHM) is a plant compound found in vine tea and in the Japanese raisin tree, both long used in East Asian folk medicine. For most of its modern life it has been sold as a supplement to ease hangovers and support the liver. More recently it has drawn a very different kind of attention: laboratory screening singled it out as a compound that can gently loosen the chemical "off switches" that build up on skin-cell genes as we age, nudging cells to behave in a more youthful way.

That single finding launched a wave of skin research. Because the aging of skin can now be estimated with a biological "clock," scientists have begun testing whether a cream made with this compound can turn that clock back. An early study using a face serum reported measurable improvements in wrinkles, smoothness, and firmness over two months, while most of the deeper evidence still comes from cells and animals.

This review examines what is known about dihydromyricetin for refreshing and protecting aging skin: how it is thought to work, what the human and laboratory evidence shows, how it is used, and where the important gaps and uncertainties remain.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**


## Recommended Reading

This section lists high-level, accessible resources that give a broad overview of dihydromyricetin and its role in skin aging.

<!-- Real-time web and PubMed searches were performed for high-level overview content on dihydromyricetin for skin rejuvenation. The prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension) were each searched by name plus the intervention via web search and on-site queries; none had content addressing dihydromyricetin for skin rejuvenation. Systematic reviews, meta-analyses, encyclopedias, and forums were excluded per the section rules. -->

* [Skin Rejuvenation by Modulation of DNA Methylation](https://pubmed.ncbi.nlm.nih.gov/39440959/) - Grönniger et al., 2024

  A concise narrative review that explains how DNA methylation (chemical tags on DNA that switch genes on or off) drives skin aging and how a mildly demethylating compound such as dihydromyricetin can be used to safely reverse age-related changes. It is the clearest overview of the epigenetic rationale behind this intervention.

* [Identification of dihydromyricetin as a natural DNA methylation inhibitor with rejuvenating activity in human skin](https://pubmed.ncbi.nlm.nih.gov/38500495/) - Falckenhayn et al., 2023

  The foundational primary study that screened 2,440 natural substances and drugs and identified dihydromyricetin as an inhibitor of the enzyme that maintains DNA methylation, then showed it lowered the biological age of skin cells and thinned epidermis in a lab skin model. Essential for understanding how the skin story began.

* [Dihydromyricetin from Ampelopsis grossedentata inhibits melanogenesis through down-regulation of MAPK, PKA and PKC signaling pathways](https://pubmed.ncbi.nlm.nih.gov/27586645/) - Huang et al., 2016

  A well-cited laboratory study documenting dihydromyricetin's ability to suppress melanin production, the basis for its proposed use as a skin-brightening and anti-dark-spot agent. It gives useful mechanistic context for the pigmentation side of skin rejuvenation.

* [Effect of the natural flavonoids myricetin and dihydromyricetin on the wound healing process in vitro](https://pubmed.ncbi.nlm.nih.gov/34907758/) - Sklenarova et al., 2021

  A primary study on human skin cells showing dihydromyricetin's anti-inflammatory and anti-glycation effects and its mixed influence on collagen-degrading enzymes, illustrating both the promise and the nuance of its skin activity.

* [Recent advances in research on vine tea, a potential and functional herbal tea with dihydromyricetin and myricetin as major bioactive compounds](https://pubmed.ncbi.nlm.nih.gov/34765268/) - Zhang et al., 2021

  A readable narrative review of vine tea, the main natural source of dihydromyricetin, summarizing its antioxidant, anti-inflammatory, and cosmetic-relevant properties and its favorable safety profile. Good background on the compound itself.

No content on this specific topic was found from the prioritized experts, so the list draws on the strongest publicly available overviews and primary sources instead.


## Grokipedia

<!-- grokipedia.com was searched directly using the browser tool for "dihydromyricetin". The intervention is covered under its chemical synonym "Ampelopsin"; the dedicated page was located and confirmed. -->

[Ampelopsin](https://grokipedia.com/page/Ampelopsin)

Grokipedia covers dihydromyricetin under its synonym "Ampelopsin" in a dedicated encyclopedia-style article summarizing its chemistry, natural sources, and pharmacology, useful as a neutral factual reference on the compound.


## Examine

<!-- examine.com was searched directly using the browser tool for "dihydromyricetin". A dedicated, accessible Examine monograph for the intervention could not be confirmed; the site returned no standalone evidence page for dihydromyricetin. -->

A direct search of examine.com did not return a dedicated evidence page for dihydromyricetin. As a result, no Examine article is cited for this intervention.


## ConsumerLab

<!-- consumerlab.com was searched directly using the browser tool for "dihydromyricetin". A dedicated CL Answer covering the intervention was located and confirmed. -->

[Dihydromyricetin (DHM) – Does It Help and Is it Safe?](https://www.consumerlab.com/answers/dihydromyricetin-dhm-does-it-help-and-is-it-safe/dhm-supplement/)

ConsumerLab's independent overview of dihydromyricetin weighs its promoted uses — liver health, blood sugar, cholesterol, hangover relief, and arthritis — against the evidence, and flags safety and supplement-quality concerns; it does not address skin outcomes.


## Systematic Reviews

No systematic review or meta-analysis has yet examined dihydromyricetin specifically for skin outcomes; the quantitative syntheses that exist address systemic (mostly liver and metabolic) effects and are listed here for context on the compound's overall evidence base.

* [Food-derived dihydromyricetin and metabolic dysfunction-associated steatotic liver disease: a preclinical systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/42022551/) - Jin et al., 2026

  A PRISMA-registered synthesis of 14 controlled animal studies finding that dihydromyricetin consistently improved liver fat, antioxidant defenses, and inflammatory markers, while stressing that human, bioavailable dosing remains undefined. It is the only meta-analysis focused solely on dihydromyricetin.

* [Efficacy of dietary polyphenol supplement in patients with non-alcoholic fatty liver disease: a network meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40416369/) - Wang et al., 2025

  A network meta-analysis of 54 randomized human trials across 13 plant polyphenols in which dihydromyricetin was one comparator, showing a modest cholesterol-lowering signal but limited by small sample sizes. It illustrates the thin human trial base for the compound.


## Mechanism of Action

Dihydromyricetin is a flavanonol (a subclass of the plant pigments called flavonoids), with the molecular formula C₁₅H₁₂O₈ and a molecular weight of about 320 g/mol. Several distinct, and partly competing, mechanisms have been proposed for its skin effects, and they are best viewed as complementary rather than mutually exclusive.

* **Epigenetic rejuvenation (the leading explanation):** Aging skin accumulates DNA methylation — chemical tags added to DNA that silence genes — in regulatory regions, dampening genes needed for keratinocyte (the main skin-cell type) vitality. Dihydromyricetin inhibits DNMT1 (DNA methyltransferase 1, the enzyme that copies methylation marks onto newly made DNA), producing a mild, global reduction in methylation that reactivates age-silenced genes and lowers the cell's "epigenetic age."

* **Antioxidant and anti-inflammatory signaling:** Dihydromyricetin scavenges reactive oxygen species (unstable molecules that damage cells), activates the Nrf2 pathway (a master switch for the cell's antioxidant defenses), and suppresses NF-κB and MAPK signaling (two relays that drive inflammation), which are central to "inflammaging" of skin.

* **Anti-glycation activity:** It binds and inhibits RAGE (the receptor for advanced glycation end products — proteins damaged by sugar), interrupting a pathway that stiffens collagen and drives cellular senescence.

* **Pigment and enzyme effects:** It inhibits tyrosinase, the rate-limiting enzyme of melanin (skin pigment) production, reducing pigmentation in cell studies.

Where these explanations compete — for example, whether visible improvements arise mainly from epigenetic reprogramming or from ordinary antioxidant and hydration effects — the human evidence cannot yet distinguish them, because the tested serum also contained other actives.

Key pharmacological properties: dihydromyricetin is poorly water-soluble and has low oral bioavailability (roughly 4%), owing to rapid phase II metabolism (glucuronidation and sulfation by UGT and SULT enzymes — conjugation enzymes that tag compounds for excretion) and a short half-life of only a few hours. It is not a strong substrate of the CYP3A4 liver enzyme (cytochrome P450 3A4, a major drug-metabolizing enzyme), though modest interactions with cytochrome enzymes have been reported. Because systemic exposure after swallowing is low, topical application directly to the skin is the delivery route with actual human skin evidence.


## Historical Context & Evolution

* **Traditional origins:** Dihydromyricetin is the principal active compound of vine tea (*Ampelopsis grossedentata*, also classified as *Nekemias grossedentata*) and is also found in the Japanese raisin tree (*Hovenia dulcis*). Vine tea has been consumed in southern China for more than a thousand years to "clear heat," soothe sore throats, and relieve the after-effects of alcohol.

* **First modern use:** Its contemporary popularity grew almost entirely around alcohol and the liver — as a hangover-recovery and liver-support supplement — supported by animal work on alcohol metabolism and a GABA-A receptor (a calming brain receptor) interaction.

* **Path to skin optimization:** Interest in skin arose in two waves. First, as a potent antioxidant flavonoid, dihydromyricetin was studied for classical skin-protective and pigment-lightening effects. The decisive shift came in 2023, when an unbiased screen for compounds that correct age-related DNA methylation identified dihydromyricetin as a DNMT1 inhibitor with rejuvenating activity in human skin, reframing it as a "skin longevity" ingredient rather than merely an antioxidant.

* **Evolution of opinion:** The field has moved from viewing skin aging as something to be masked to treating it as a biological process with measurable markers. Dihydromyricetin became a test case for whether modulating one hallmark of aging — epigenetic change — can reverse a biological age clock in living skin. This view is promising but not settled: the pivotal human data come from a single uncontrolled study by a cosmetics manufacturer, and independent replication with proper controls has not yet emerged. The current enthusiasm should be read as an early-stage hypothesis gaining support, not as an established consensus.


## Expected Benefits

The benefits below are framed for a proactive, health-focused adult considering dihydromyricetin (predominantly as a topical) as part of a skin-longevity routine. Evidence for skin outcomes is early: the strongest human signal comes from one uncontrolled study, and the remainder is preclinical.


### Low 🟩

#### Epigenetic Rejuvenation and Improvement in Visible Signs of Aging (Topical)

By inhibiting DNMT1 and reducing age-associated DNA methylation, a topical dihydromyricetin serum lowered the skin's biological ("epigenetic") age and was accompanied by visible improvements. The evidence basis is one prospective, single-cohort study of 60 adults (Fitzpatrick phototypes I–VI) applying a serum twice daily for 8 weeks, supported by cell and 3-dimensional skin-model work. Important nuance: the study had no placebo or vehicle-controlled arm, was conducted and funded by a cosmetics manufacturer (Beiersdorf AG, a conflict of interest given its commercial stake in such products), and the serum also contained hyaluronic acid and other actives plus a high-factor sunscreen, so the visible improvements cannot be attributed to dihydromyricetin alone.

**Magnitude:** Mean epidermal DNA-methylation age fell ~2.1 years over 8 weeks (with 40% of participants improving ≥5 years); periorbital wrinkle visibility decreased ~13.9%, skin roughness ~4–5%, and dermal density increased ~10.4%.

#### Antioxidant and Anti-Inflammatory Skin Support

Dihydromyricetin scavenges reactive oxygen species, activates Nrf2 antioxidant defenses, and suppresses NF-κB and MAPK inflammatory signaling, which plausibly protects against oxidative and inflammatory drivers of skin aging ("inflammaging"). The evidence basis is consistent laboratory and animal data plus the improved texture and radiance reported in the human serum study, though that study did not isolate an antioxidant endpoint. This benefit is mechanistically robust but not yet demonstrated by a skin-specific human antioxidant measurement.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Skin Brightening and Anti-Hyperpigmentation

Dihydromyricetin inhibits tyrosinase and lowers melanin production by down-regulating MAPK, PKA (protein kinase A), and PKC (protein kinase C) signaling, suggesting a role against dark spots and uneven tone. The basis is in vitro only — pigment-cell lines and isolated enzyme assays — with no human topical pigmentation trials, so this remains a laboratory-stage hypothesis.

#### Anti-Glycation and Collagen Preservation

By acting as a RAGE inhibitor, dihydromyricetin blunts advanced-glycation-driven senescence and helped preserve collagen and skin elasticity in a rat glycation-aging model and in cultured human fibroblasts. The basis is animal and cell data only; no human study has tested dihydromyricetin for glycation-related skin aging, and its effect on collagen-degrading enzymes was mixed across cell types.

#### Anti-Acne Activity

Dihydromyricetin is directly bactericidal against *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and dampens TLR2/NF-κB/MAPK inflammation (TLR2 is an immune sensor for microbes); a 0.1% topical gel matched standard adapalene and clindamycin treatment in a mouse model. The basis is in vitro plus a single rodent model, with no human acne trials.

#### Wound Healing and Barrier Repair Support

Dihydromyricetin-loaded topical hydrogels and nanofiber dressings accelerated closure and reduced inflammation in rodent wound models, including diabetic wounds, pointing to barrier-repair potential. The basis is animal and formulation studies only, and wound healing is an adjacent rather than a direct rejuvenation endpoint.


## Benefit-Modifying Factors

* **Genetic polymorphisms:** Variants in phase II conjugation enzymes (UGT and SULT) and in DNA-methylation machinery may alter how much dihydromyricetin reaches and acts on skin cells, though no skin-specific pharmacogenetic data exist. This is theoretical and relevant mainly to oral use.

* **Baseline biomarker levels:** Individuals whose skin is "epigenetically older" than their chronological age, or who carry a high glycation burden (elevated blood sugar), have more room to benefit from an agent that targets methylation and glycation pathways.

* **Sex-based differences:** The human serum study included both sexes and found improvements irrespective of gender, but women were over-represented and hormonal influences on skin aging (e.g., post-menopausal collagen loss) may modify the size of any real-world effect.

* **Pre-existing health conditions:** Poorly controlled diabetes (high glycation) and chronic inflammatory skin conditions may shift the balance of benefit, potentially increasing the relevance of dihydromyricetin's anti-glycation and anti-inflammatory actions.

* **Age:** Benefits were seen across a 40–70-year range and did not depend on chronological age, suggesting older adults at the upper end of the target range can still respond; however, thinner, more fragile older skin may tolerate actives differently.


## Potential Risks & Side Effects

Dihydromyricetin has an unusually clean safety record in both traditional use and modern trials, so the documented risks are few and mostly mild or theoretical. Risks are framed for a proactive adult, distinguishing the evidenced topical route from the unvalidated oral route.


### Low 🟥

#### Gastrointestinal Discomfort (Oral Use)

When swallowed as a supplement — the route used for hangover and liver indications rather than for skin — dihydromyricetin is generally well tolerated, but mild stomach upset or nausea can occur. The evidence basis is human hangover and metabolic trials, which report no serious adverse events attributed to the compound. This risk is relevant only to those taking oral dihydromyricetin hoping for a skin benefit, which currently lacks supporting evidence.

**Magnitude:** Not quantified in available studies.

#### Skin Irritation or Sensitization (Topical)

As with any topical active, dihydromyricetin serums can in principle cause redness, stinging, or contact sensitization, particularly on sensitive or compromised skin. The evidence basis is the 8-week study of 60 participants, in which no adverse events related to the investigational product were reported and tolerability was rated good across all skin types; standard patch-testing caution nonetheless applies.

**Magnitude:** Not quantified in available studies.


### Speculative 🟨

#### Uncertain Long-Term Effects of Broad Epigenetic Modulation

Because dihydromyricetin inhibits DNMT1 in a non-gene-specific way, there is a theoretical concern that sustained use could alter methylation at unintended genes. The developers report the effect is mild and self-limiting and observed no reactivation of skin cancer-related genes in their assays, but human safety beyond 8 weeks is unstudied, so this remains a mechanistic, not an observed, concern.

#### Additive Sedation and Altered Alcohol Handling (Oral, High Dose)

Dihydromyricetin modulates the GABA-A receptor and influences alcohol-metabolizing enzymes, so high oral doses could theoretically add to the effects of sedatives or alcohol. The basis is preclinical work and the compound's hangover-supplement context; it is not relevant to topical skin use and has not produced reported harm at typical doses.


## Risk-Modifying Factors

* **Genetic polymorphisms:** No validated genetic variants are known to raise dihydromyricetin's skin risk; theoretically, differences in conjugation enzymes (UGT) affect systemic exposure and thus any oral-related effects, not topical tolerability.

* **Baseline biomarker levels:** A compromised skin barrier (low hydration, high transepidermal water loss) may predispose to irritation from any topical active, including dihydromyricetin serums.

* **Sex-based differences:** No sex-specific safety signal has been identified; tolerability was comparable across genders in the human study.

* **Pre-existing health conditions:** People with known flavonoid or plant-extract allergies, active eczema, or rosacea may be more prone to topical irritation. For oral use, those on sedatives or with significant alcohol intake warrant extra caution because of the GABA-A interaction.

* **Age:** Older adults with thinner, drier skin may experience more irritation from actives; introducing the product gradually is prudent at the upper end of the target age range.


## Key Interactions & Contraindications

* **Prescription drug interactions:** For oral dihydromyricetin, additive central-nervous-system depression is possible with benzodiazepines (e.g., diazepam, alprazolam) and other sedative-hypnotics via GABA-A modulation — caution; consequence is excess drowsiness. Modest effects on cytochrome P450 enzymes create a theoretical interaction with narrow-therapeutic-index drugs metabolized by CYP3A4 (e.g., certain statins, calcineurin inhibitors) — monitor.

* **Over-the-counter medication interactions:** Combined with alcohol or OTC sleep aids containing antihistamines (e.g., diphenhydramine), oral dihydromyricetin could add to sedation — caution. Topically, layering with OTC exfoliating acids (glycolic, salicylic) may increase irritation — separate applications.

* **Supplement interactions:** Other GABA-active supplements (valerian, kava, high-dose magnesium glycinate) may compound sedation with oral use — monitor. There are no reported adverse supplement interactions for topical use.

* **Supplements with additive effects:** For skin, dihydromyricetin plausibly has additive antioxidant or anti-glycation effects with topical vitamin C, niacinamide, and carnosine, and additive brightening effects with other tyrosinase inhibitors (e.g., alpha-arbutin, kojic acid) — generally desirable but increases the chance of cumulative irritation.

* **Other intervention interactions:** When used alongside prescription retinoids (tretinoin) or in-office procedures (peels, lasers), topical dihydromyricetin may add to irritation on freshly treated skin — separate in time and monitor.

* **Populations who should avoid it:** Pregnant or breastfeeding individuals should avoid oral dihydromyricetin (absolute caution — insufficient safety data); people with a known allergy to vine tea, *Hovenia*, or related flavonoids should avoid both routes. Those with significant alcohol-use disorder or on chronic sedatives should avoid high-dose oral use (caution — additive sedation).


## Risk Mitigation Strategies

* **Patch test before facial use:** Apply the serum to a small area (inner forearm or behind the ear) for 2–3 days before full-face use to detect irritation or sensitization early — this mitigates topical skin irritation and allergic reactions.

* **Introduce gradually:** Start with once-daily application (evening) for the first 1–2 weeks, then increase to twice daily if tolerated — this limits cumulative irritation, especially in older or sensitive skin.

* **Do not substitute for sun protection:** Pair topical dihydromyricetin with a broad-spectrum sunscreen of SPF 30–50+, applied every morning — this prevents ultraviolet-driven epigenetic aging, which the active alone does not block (the human study explicitly co-applied SPF 50+).

* **Separate strong actives:** Avoid applying dihydromyricetin at the same time as prescription retinoids or exfoliating acids; alternate mornings/evenings or days — this reduces additive irritation.

* **Limit oral dosing and avoid stacking sedatives:** If using oral dihydromyricetin at all (an unproven route for skin), keep to studied ranges and avoid combining with alcohol or sedative medications — this mitigates the risk of excess drowsiness from GABA-A modulation.

* **Reassess after 8–12 weeks:** Because long-term epigenetic effects are unstudied, periodically pausing and reassessing rather than using indefinitely without review mitigates the theoretical concern of prolonged broad methylation change.


## Therapeutic Protocol

* **Standard topical protocol (best-evidenced):** A facial serum with dihydromyricetin as the key active, applied twice daily (morning and night) to clean, dry face and neck, followed by broad-spectrum sunscreen in the morning. In the pivotal study this regimen used roughly ≥10 g of serum over 4 weeks and ran for 8 weeks; leading formulators combine it with hyaluronic acid and supportive antioxidants.

* **Popularizing groups:** The topical "skin longevity" approach was developed and popularized by Beiersdorf AG's research group in collaboration with the German Cancer Research Center; this industry origin is a conflict of interest that should be weighed when interpreting the protocol.

* **Alternative approaches:** An oral supplement route exists (doses commonly 300–1,000 mg/day for liver and hangover uses) but has no evidence for skin outcomes and, given ~4% bioavailability, is unlikely to deliver meaningful amounts to skin; it is presented as an unvalidated alternative, not an equivalent option.

* **Best time of day:** Topical use is split morning and night; because ultraviolet light drives epigenetic aging, the morning application is paired with sunscreen. Oral dosing, if used, is typically taken with food.

* **Half-life and dosing frequency:** Dihydromyricetin's short systemic half-life (a few hours) and rapid metabolism are the practical reason for twice-daily topical application and, for oral use, split rather than single dosing.

* **Genetic considerations:** No skin-specific pharmacogenetic guidance exists; variants in conjugation enzymes (UGT) chiefly affect oral exposure and are not established as protocol modifiers for topical use.

* **Sex-based considerations:** Response did not differ meaningfully by sex in the human study; no sex-specific dose adjustment is defined.

* **Age considerations:** Benefits were seen across ages 40–70; older adults may begin with once-daily application to accommodate thinner, more reactive skin before escalating.

* **Baseline biomarkers:** A higher baseline "epigenetic age gap" or glycation burden may predict greater response, but this is not yet used to guide dosing.

* **Pre-existing conditions:** Those with sensitive or barrier-impaired skin should adopt a slower titration; there is no defined contraindication to topical use beyond allergy.


## Discontinuation & Cycling

* **Lifelong vs. short-term:** Topical dihydromyricetin is a maintenance cosmetic intervention rather than a one-time treatment; measured benefits were observed at 8 weeks and there is no evidence they persist after stopping.

* **Expected course on stopping:** Because age-related methylation marks re-accumulate over time, epigenetic and visible gains are expected to gradually reverse after discontinuation, though this has not been formally tracked.

* **Withdrawal effects:** No withdrawal syndrome is known for either topical or oral dihydromyricetin.

* **Tapering:** No taper is required; the product can simply be stopped.

* **Cycling:** No cycling schedule has been established for efficacy. Given unstudied long-term epigenetic effects, some practitioners favor periodic reassessment (e.g., a review every 8–12 weeks) rather than formal cycling.


## Sourcing and Quality

* **Source and form:** Dihydromyricetin is extracted from vine tea (*Ampelopsis grossedentata*); for skin it is used both as a raw cosmetic active and within branded ingredients (for example, dihydromyricetin-based cosmetic actives such as Epicelline). For topical rejuvenation, a finished serum formulation matters more than raw powder because delivery and stability are formulation-dependent.

* **What to look for:** Choose products that specify dihydromyricetin content or a standardized extract (raw material is often standardized to ≥98% purity), and, for supplements, look for third-party testing (e.g., NSF, USP, or an independent certificate of analysis) covering identity, potency, and contaminants.

* **Contaminant testing:** Because it is plant-derived, confirm testing for heavy metals and pesticide residues; vine tea sourcing quality varies.

* **Reputable options:** Cosmetic dihydromyricetin actives from established ingredient houses and serums from manufacturers that publish clinical or stability data are preferable; for oral powders, brands providing batch certificates of analysis are preferred. Compounding pharmacies are generally not involved, as dihydromyricetin is a cosmetic/supplement ingredient rather than a prescription drug.


## Practical Considerations

* **Time to effect:** In the human study, biological-age and visible changes were measured over 8 weeks, with some clinical improvements already significant at 4 weeks; users should expect gradual results over roughly 1–2 months, not overnight change.

* **Common pitfalls:** Expecting an oral supplement to rejuvenate skin (no evidence and poor bioavailability); skipping daily sunscreen and thereby allowing continued ultraviolet-driven aging; combining it with too many strong actives at once and provoking irritation; and judging results without standardized before/after photos.

* **Regulatory status:** For skin, dihydromyricetin is used as a cosmetic ingredient, not an approved drug, so products are marketed for appearance rather than to treat disease. As an oral product it is sold as a dietary supplement (a novel-food-approved vine tea component in some jurisdictions), which means less pre-market oversight of claims.

* **Cost and accessibility:** Dihydromyricetin skin serums are still an emerging, relatively niche category with limited product availability, though the raw material itself is inexpensive; access is easier for oral supplements, which are not the evidenced route for skin.

* **Route matters:** The single most practical point is that topical delivery — not swallowing — is where the human skin evidence lies.


## Interaction with Foundational Habits

* **Sleep:** Indirect and potentially supportive. Skin repair and cell turnover peak during sleep, so consistent sleep complements any rejuvenation routine; separately, oral dihydromyricetin's GABA-A activity may promote mild relaxation, though this is irrelevant to topical use. Practical point: apply the night-time serum as part of a wind-down routine.

* **Nutrition:** Potentiating. Because dihydromyricetin targets glycation (sugar-driven protein damage), a lower-sugar, lower-advanced-glycation-end-product diet plausibly reinforces its anti-glycation mechanism; vine tea is also a dietary source of the compound. Practical point: pairing with antioxidant-rich foods and controlled blood sugar is complementary.

* **Exercise:** Largely neutral to mildly supportive. At topical doses there is no evidence dihydromyricetin blunts exercise adaptations (a theoretical concern only for very high-dose oral antioxidants); regular exercise improves skin perfusion, which supports skin health. Practical point: cleanse sweat before applying serum to reduce irritation.

* **Stress management:** Indirect. Chronic stress raises cortisol and inflammation, accelerating skin aging; dihydromyricetin's anti-inflammatory action addresses a downstream consequence rather than the stressor itself. Practical point: stress reduction and the topical work on complementary parts of the same aging pathway.


## Monitoring Protocol & Defining Success

For a predominantly topical cosmetic intervention, routine laboratory monitoring is generally unnecessary; the markers below are optional and most relevant when tracking the underlying rejuvenation and glycation rationale or when dihydromyricetin is also used orally. Baseline assessment before starting should combine standardized facial photographs and, where available, an objective skin measurement, plus optional bloodwork if the systemic anti-glycation rationale is being pursued.

Ongoing monitoring is best done on a slow cadence: reassess visible and structural skin parameters at 4 weeks, 8 weeks, and then every 3–6 months; repeat any optional bloodwork every 6–12 months.

Baseline and ongoing lab and skin markers:

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|----------------|
| Biological skin age (epidermal DNA-methylation clock) | Lower than chronological age | Tracks the primary epigenetic mechanism directly | Research-grade tape-strip assay; not yet routinely available clinically; no conventional-care equivalent exists |
| Dermal density / elasticity (ultrasound or cutometer) | Improvement vs. personal baseline | Objective structural readout of firmness and thickness | Operator- and device-dependent; standardize site and settings; pairs well with standardized photos |
| Hemoglobin A1c (HbA1c) | <5.4% (functional); conventional "normal" <5.7% | Reflects glycation load feeding the AGE–RAGE aging pathway | Reflects ~3-month average blood sugar; fasting not required |
| Fasting glucose | 75–90 mg/dL (functional); conventional 70–99 mg/dL | Same glycation rationale, shorter-term | Morning fasting sample; best paired with fasting insulin |
| High-sensitivity C-reactive protein (hs-CRP) | <1.0 mg/L (functional); conventional <3.0 mg/L | Systemic inflammation ("inflammaging") that accelerates skin aging | Avoid testing during acute infection or injury, which transiently elevates it |
| Alanine aminotransferase / aspartate aminotransferase (ALT/AST) | ALT <25 U/L (men) / <20 U/L (women), functional; conventional up to ~40 U/L | Only relevant with long-term high-dose oral use of this liver-active compound | Fasting preferred; not needed for topical-only use |

Qualitative markers of success:

* Smoother skin texture and reduced roughness on touch and in photos
* Softer appearance of fine lines and periorbital wrinkles ("crow's feet")
* Improved firmness and elasticity
* Brighter, more even tone and radiance
* Good tolerability — absence of persistent redness, stinging, or breakouts


## Emerging Research

* **Topical epigenetic rejuvenation (key new human evidence):** The first in vivo study of a [dihydromyricetin-containing serum](https://pubmed.ncbi.nlm.nih.gov/42034839/) (Qi et al., 2026) reported reduced epidermal methylation age and improved wrinkles, roughness, and dermal density over 8 weeks across diverse skin types — but it was single-cohort, industry-funded, and lacked a vehicle-controlled arm, which the authors flag as the central limitation to be addressed next.

* **Senescent-cell targeting (mechanistic expansion):** A 2026 study in Nature Communications, [dihydromyricetin targets senescent cells via PRDX2](https://pubmed.ncbi.nlm.nih.gov/41792133/) (Xu et al., 2026), reported that dihydromyricetin protects senescent fibroblasts and acts through peroxiredoxin 2 (PRDX2, an antioxidant protein) to alleviate age-related conditions — a strengthening line of evidence relevant to skin, since fibroblast senescence drives dermal aging.

* **Anti-glycation mechanism (supporting direction):** A 2025 rat and cell study, [dihydromyricetin as a RAGE inhibitor](https://pubmed.ncbi.nlm.nih.gov/40507131/) (Wang et al., 2025), showed it preserved collagen and elasticity in glycation-induced skin aging, reinforcing a second, non-epigenetic pathway for benefit.

* **Ongoing clinical trials (systemic, not skin):** No registered trial yet tests dihydromyricetin for skin. A Phase 1 dose-escalation safety study, [NCT05623501](https://clinicaltrials.gov/study/NCT05623501) (alcohol-associated liver disease, ~12 participants), will help define human safety and pharmacokinetics of oral dosing, and a Phase 2 study, [NCT03606694](https://clinicaltrials.gov/study/NCT03606694) (type 2 diabetes, ~24 participants, glycemic control and insulin sensitivity), speaks to the glycation pathway relevant to skin aging.

* **Future research that could change the picture:** The decisive next step is a randomized, vehicle-controlled trial of a topical dihydromyricetin formulation isolating the active from co-ingredients, with longer follow-up and head-to-head comparison against gold-standard retinoids; independent (non-industry) replication and studies of durability and long-term epigenetic safety are equally important. Evidence could move in either direction — a controlled trial might confirm a genuine effect or reveal that co-formulated actives and sunscreen accounted for much of the observed benefit.


## Conclusion

Dihydromyricetin is a plant flavonoid, best known as a hangover and liver supplement, that has recently been repositioned as a possible "skin longevity" ingredient. Its appeal rests on an unusual mechanism: it gently removes the chemical marks that build up on skin-cell genes with age, and it also fights oxidative stress, inflammation, and sugar-driven damage. Applied to the skin as a serum, it has been reported to turn back a biological "age clock" and to modestly smooth wrinkles, improve firmness, and increase skin density over about two months, with a reassuring safety and tolerability record.

The evidence, however, is early and thin. The main human study was small, ran for only eight weeks, had no placebo comparison, was funded by a company that sells such products, and used a serum that also contained other active ingredients — so the visible improvements cannot be credited to dihydromyricetin alone. The rest of the support comes from cells and animals, and the pigment, anti-acne, and wound-healing effects remain laboratory findings. Taken orally, it is unlikely to reach skin in useful amounts. For someone weighing it as part of a proactive routine, dihydromyricetin is a promising but unproven topical whose real value awaits controlled, independent testing, and one that does not replace sun protection.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**